<DOC>
	<DOCNO>NCT00242996</DOCNO>
	<brief_summary>RATIONALE : Giving colony-stimulating factor , G-CSF , monoclonal antibody , rituximab , chemotherapy , cyclophosphamide , help stem cell move patient 's bone marrow blood collect store peripheral stem cell transplant . Giving chemotherapy , carmustine , etoposide , cyclophosphamide , transplant stop growth cancer cell stop divide kill . The stem cell return patient replace blood-forming cell destroy chemotherapy . More rituximab give transplant kill remain cancer cell . PURPOSE : This phase II trial study well give rituximab together cyclophosphamide G-CSF follow combination chemotherapy work treat patient undergo autologous stem cell transplant follow rituximab GM-CSF refractory diffuse large B-cell lymphoma .</brief_summary>
	<brief_title>Rituximab , Cyclophosphamide , G-CSF Followed By Combination Chemotherapy Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab GM-CSF Refractory Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine disease-free overall survival patient refractory diffuse large B-cell lymphoma treat stem cell mobilization comprise rituximab , cyclophosphamide , filgrastim ( G-CSF ) follow high-dose chemotherapy comprise carmustine , etoposide , cyclophosphamide autologous peripheral blood stem cell transplantation , rituximab , sargramostim ( GM-CSF ) . - Determine potential infectious complication patient treat regimen . - Determine effect GM-CSF antibody-dependent cellular cytotoxicity patient treat regimen . OUTLINE : Stem cell mobilization : Patients receive rituximab IV 4-8 hour day 1 , 5 , 8 , 13 . Patients also receive cyclophosphamide IV 1-2 hour day 9 filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 10 continue adequate number peripheral blood stem cell ( PBSC ) collect . High-dose preparative regimen : Patients receive carmustine IV 2 hour day -6 , etoposide IV 4 hour day -4 , cyclophosphamide IV 2 hour day -2 . Autologous PBSC transplantation : Patients undergo autologous PBSC transplantation day 0 . Patients receive sargramostim ( GM-CSF ) SC daily begin day 6 continue blood count recover . Post-transplant regimen : Patients receive GM-CSF SC daily day 42-73 , 177-208 , 362-393 , 543-574 , 727-758 . Patients also receive rituximab IV 4-8 hour day 45 , 52 , 59 , 66 , 180,187 , 194 , 201 , 365 , 372 , 379 , 386 , 546 , 553 , 560 , 567 , 730 , 737 , 744 , 751 . After completion study treatment , patient follow periodically 10 year . PROJECTED ACCRUAL : A total 44 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis diffuse large Bcell lymphoma , meet 1 follow criterion : Failed achieve least partial remission Failed respond prior primary therapy salvage chemotherapy Disease progression within 6 week achieve remission CD20 expression diagnosis relapse No 4 prior regimen use chemotherapy , radiotherapy , immunotherapy The addition radiotherapy monoclonal antibody chemotherapy consider 1 treatment regimen provide addition part initial treatment plan The addition therapy due lack response poor response consider additional treatment regimen whether give front line salvage set PATIENT CHARACTERISTICS : Performance status ECOG 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Direct bilirubin ≤ 2 mg/dL AST ALT &lt; 3 time upper limit normal Renal Creatinine ≤ 2.0 mg/dL Cardiovascular Ejection fraction ≥ 40 % Pulmonary DLCO ≥ 60 % predict Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 2 year except curatively treat basal cell squamous cell skin cancer carcinoma situ cervix No active infection require oral IV antibiotic HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics See Radiotherapy Chemotherapy See Disease Characteristics Radiotherapy See Disease Characteristics No prior radioimmunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
</DOC>